Venus team is working on target-based drug delivery for cancer treatment. The Company has designed a platform technology with a novel concept of triple conjugate i.e., Drug-Protein-Polymer-Conjugate (DPPC) for the purpose. Based on the specificity of the target organ, various components of DPPC can be rationally selected.
Formulation development is the core (sanctum sanctorum) art and science of preparation.More
With an aim to preserve the life of existing antibiotics and to guide better clinical decisionsMore
Copyright © 2019 VMRCINDIA All Rights Reserved